CyMedica QB1 System now commercially available for treatment of quadriceps muscle atrophy

Scottsdale-based CyMedica Orthopedics™, Inc. announced the commercial launch of the CyMedica QB1™ System for the treatment of quadriceps muscle atrophy at the Arthroscopy Association of North American Arthroscopic Society for Sports Medicine (AANA) annual meeting in Los Angeles last week. The product was first shown at the AAOS meeting in March.

Delivering professional athlete rehabilitation for every patient, the QB1 capitalizes on proprietary revolutionary NMES (neuromuscular electrical stimulation) technology for the treatment of quadriceps muscle atrophy and combines three best-in-class products: a postoperative knee brace, a form-fitting conductive garment, and a user friendly NMES control interface. The device substantially simplifies the delivery of "at home" NMES treatment and encourages patient compliance.

"The CyMedica QB1 knee brace and wrap is a game changer in orthopedics," says Dr. Struan Coleman, CyMedica cofounder, specialist in sports medicine at the Hospital for Special Surgery and NY Mets Head Team Physician. "The QB1 will allow the orthopedic surgeon to treat every patient like a professional athlete by initiating neuromuscular activation immediately following knee surgery. For the first time, the patient, the surgeon and the physical therapist will all be equally involved in postoperative rehabilitation of the knee."

The QB1 NMES system delivers high intensity electrical muscle stimulation while maintaining patient comfort. The QB1's proprietary closed-loop system monitors and adjusts the electrical stimulation power delivered to the patient to ensure consistent and comfortable quadriceps activation.

"We are extremely pleased with the response from surgeons at the AAOS and AANA meetings," said Robert Morocco, President and CEO of CyMedica Orthopedics.